Vicentra Closes Eur 65M (Usd 74M) Series C Funding To Expand Footprint Of World'S Smallest Insulin Pump Across Europe

Dec 16, 2021•about 4 years ago

Amount Raised

€65 Million

Round Type

series c

Utrecht

Description

ViCentra, the company behind Kaleido, the world's smallest and lightest wearable insulin pump ("patch pump"), announces the closing of a EUR 65 million (USD 74 million) Series C financing. The investment round was led by new investor Partners in Equity BV, the Amsterdam based Venture Capital firm with a long-term focus. Existing investors LSP, INKEF Capital and Health Innovations also participated in the investment.

Company Information

Company

Vi Centra

Location

Utrecht, Utrecht, Netherlands

About

ViCentra B.V., with headquarters in Utrecht, the Netherlands develops, manufactures and markets next generation insulin pumps and other products to treat people with diabetes. The company's flagship product is the Kaleido insulin pump which is CE marked and commercially released in certain European countries. ViCentra was founded in 2013 and is backed by Health Innovations, INKEF Capital, LSP, Invest-NL, Partners in Equity BV and Kreos Capital. The highly experienced team has expertise in scaling manufacturing, commercialisation and regulatory filing. More information about ViCentra can be found at www.hellokaleido.com.

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Vicentra Closes Eur 65M (Usd 74M) Series C Funding To Expand Footprint Of World'S Smallest Insulin Pump Across Europe

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information